美新临床实验政策引担忧

2018-01-27 张章 科学网

近日,美国基本行为研究人员将迎来一项新政策。该政策为其联邦资助研究引入了若干新的规定,其中许多研究是美国国家卫生研究院(NIH)正在考虑的临床实验。许多研究人员认为这项政策毫无意义,而且会妨碍他们的工作。不过,NIH官员最近提出的修订版本减轻了人们的一些担忧。

美国立卫生研究院或将脑部扫描研究定义为临床实验。图片来源:Thierry Berrod, Mona Lisa Production/Science Source

近日,美国基本行为研究人员将迎来一项新政策。该政策为其联邦资助研究引入了若干新的规定,其中许多研究是美国国家卫生研究院(NIH)正在考虑的临床实验。许多研究人员认为这项政策毫无意义,而且会妨碍他们的工作。不过,NIH官员最近提出的修订版本减轻了人们的一些担忧。

“但这仍是一个问题,只不过没有原来的版本那么可怕。”行为与脑科学协会联合会(FABBS)前主席、哈佛大学认知心理学家Jeremy Wolfe说。

相关条例是NIH在2014年发布、直到去年才开始实施的新临床实验定义的一部分。当科学家使用诸如核磁共振成像等工具探索大脑的正常工作原理时,他们不认为这些研究是临床实验,因为他们没有测试药物或其他治疗方法。但新定义推翻了这一理论。于是,新变化对研究人员提出了一些新的要求,例如需要提交临床实验申请和在相关机构进行注册等。

从那以后,研究人员和大学团体就给NIH发送了大量的电子邮件和评论,尤其是在NIH发布了一系列的案例研究证实此类基础研究将被包括在临床实验内之后。去年9月,3500多位科学家签署了一封公开信,要求NIH推迟实施这项政策。

NIH副院长Michael Lauer表示,基础科学经费评审可能会像以前一样进入同行评审小组,而不是临床实验小组。而一个1小时的在线课程可能足以满足新的培训要求。这些“以完全合理的方式解决了许多问题。”Wolfe说。

然而,争议还没有结束。FABBS 执行主席Paula Skedsvold认为,相关定义仍然是模糊的。Wolfe表示,研究人员希望NIH能够为“机械研究”制定一个单独的注册和报告选项,这将使基础研究人员能更加透明,但让公众在填写申请材料时不会感到困惑。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1941555, encodeId=830c1941555f3, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Nov 12 19:54:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284878, encodeId=44152848e8b4, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Feb 04 00:19:48 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283080, encodeId=fa9c28308032, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jan 29 06:55:28 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260304, encodeId=bd2e1260304cc, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Jan 29 00:54:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282582, encodeId=089e2825822e, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Sat Jan 27 15:00:51 CST 2018, time=2018-01-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1941555, encodeId=830c1941555f3, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Nov 12 19:54:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284878, encodeId=44152848e8b4, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Feb 04 00:19:48 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283080, encodeId=fa9c28308032, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jan 29 06:55:28 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260304, encodeId=bd2e1260304cc, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Jan 29 00:54:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282582, encodeId=089e2825822e, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Sat Jan 27 15:00:51 CST 2018, time=2018-01-27, status=1, ipAttribution=)]
    2018-02-04 1e0f8808m18(暂无匿称)

    学习了.谢谢分享.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1941555, encodeId=830c1941555f3, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Nov 12 19:54:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284878, encodeId=44152848e8b4, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Feb 04 00:19:48 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283080, encodeId=fa9c28308032, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jan 29 06:55:28 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260304, encodeId=bd2e1260304cc, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Jan 29 00:54:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282582, encodeId=089e2825822e, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Sat Jan 27 15:00:51 CST 2018, time=2018-01-27, status=1, ipAttribution=)]
    2018-01-29 1e0f8808m18(暂无匿称)

    学习了.谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1941555, encodeId=830c1941555f3, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Nov 12 19:54:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284878, encodeId=44152848e8b4, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Feb 04 00:19:48 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283080, encodeId=fa9c28308032, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jan 29 06:55:28 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260304, encodeId=bd2e1260304cc, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Jan 29 00:54:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282582, encodeId=089e2825822e, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Sat Jan 27 15:00:51 CST 2018, time=2018-01-27, status=1, ipAttribution=)]
    2018-01-29 bioon3
  5. [GetPortalCommentsPageByObjectIdResponse(id=1941555, encodeId=830c1941555f3, content=<a href='/topic/show?id=108022e76b3' target=_blank style='color:#2F92EE;'>#临床实验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22776, encryptionId=108022e76b3, topicName=临床实验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6779163, createdName=liuhuangbo, createdTime=Mon Nov 12 19:54:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284878, encodeId=44152848e8b4, content=学习了.谢谢分享., beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Feb 04 00:19:48 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=283080, encodeId=fa9c28308032, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Mon Jan 29 06:55:28 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260304, encodeId=bd2e1260304cc, content=<a href='/topic/show?id=1ed65e476b8' target=_blank style='color:#2F92EE;'>#政策#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57476, encryptionId=1ed65e476b8, topicName=政策)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=322359, createdName=bioon3, createdTime=Mon Jan 29 00:54:00 CST 2018, time=2018-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=282582, encodeId=089e2825822e, content=好好文章学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K1RUfOKQohib4bXhDtxVgOA9VcKY1LUZkCOmr0v3WupxANz2ibibNHkdevtSruvrhyI29IjXdtvUV48/0, createdBy=6ff82057534, createdName=139****5926, createdTime=Sat Jan 27 15:00:51 CST 2018, time=2018-01-27, status=1, ipAttribution=)]
    2018-01-27 139****5926

    好好文章学习了

    0

相关资讯

英国癌症研究中心携手Bicycle Therapeutics进行实体瘤临床试验

英国癌症研究中心药物研发中心将资助Bicycle Therapeutics研发的二环肽偶联药物BT1718在晚期实体瘤病人身上进行1a/1b期临床试验,这项临床试验将由英国癌症研究中心和Bicycle一起管理进行。 BT17181是一种靶向膜型1类基质金属蛋白酶(MT1-MTP)的新药,这种蛋白质在三阴性乳腺癌、非小细胞肺癌等一系列实体瘤中高表达。 这项临床试验的项目负责人Udai Ban

重磅!Nat Med报道HIV抗体临床实验获得成功

一个由洛克菲勒大学研究人员和科隆大学及德国感染研究中心的Florian Klein教授领导的研究团队在人体中检测了一个新的HIV中和抗体(10-1074)的效果,相关临床试验数据最近发表在《Nature Medicine》上。 过去几年里,研究人员发现了一些新的HIV中和抗体。“这些抗体作用很强大,可有效中和一系列不同的HIV病毒株,因此它们在发展HIV疫苗过程中发挥重要作用。”Klei

Circulation:共享数据的可用性及其在心脏代谢临床试验中的应用

目前,患者水平临床试验数据的共享已被广泛认可。但是,人们对于如何将这些数据更广泛用于心脏代谢疾病仍知之甚少。AHA 2017科学年会上发布的一项最新研究评估了心脏代谢临床试验共享数据的可用性及其应用。

SCIENCE:干细胞疗法证实安全

人类首次来自诱导多能干细胞(IPS,Induced Pluripotent Stem Cells)分化的上皮细胞的临床试验终于出成果啦!

BMC Med Research Method:进行低风险临床试验前,患者对知情同意书的态度如何?

知情同意书(Information Consent Form, ICF)是保护受试者个体权益的重要武器,它既规范临床医疗行为,又约束研究行为的伦理原则。

亨廷顿症有望被治愈:研发中的新药能有效降低致病蛋白含量

亨廷顿舞蹈症(下称“亨廷顿症”)被称为“致命的舞蹈”。其患者好像在手舞足蹈,真实情况是,因为致病蛋白杀死越来越多的脑细胞,他们正在慢慢丧失运动能力和生活的自理能力,最终连吞咽和呼吸都十分困难。人类一直缺乏有效治疗亨廷顿症的药物。北京时间12月11日晚8时许,BBC(英国广播公司)发布消息称,导致亨廷顿症的罪魁祸首、其致病蛋白第一次被人类制服:一个临床实验结果显示,一款新研发的药物能安全地、有效